Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: jakesz r. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31. Lancet. 2015. PMID: 26040499 Clinical Trial.
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Forbes JF, et al. Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11. Lancet. 2016. PMID: 26686313 Free PMC article. Clinical Trial.
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Sölkner L, Fesl C, Gnant M, Fitzal F. Wimmer K, et al. Among authors: jakesz r. Breast Cancer Res Treat. 2024 Jun;205(2):227-239. doi: 10.1007/s10549-023-07186-6. Epub 2024 Jan 25. Breast Cancer Res Treat. 2024. PMID: 38273214 Free PMC article.
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Sölkner L, Fesl C, Gnant M, Fitzal F. Wimmer K, et al. Among authors: jakesz r. Breast Cancer Res Treat. 2024 Jul;206(2):441. doi: 10.1007/s10549-024-07351-5. Breast Cancer Res Treat. 2024. PMID: 38704775 Free PMC article. No abstract available.
German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer.
AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members; Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F. AGO, et al. Eur J Cancer. 2013 Jul;49(10):2277-83. doi: 10.1016/j.ejca.2013.01.034. Epub 2013 Mar 13. Eur J Cancer. 2013. PMID: 23490652
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.
Gnant M, Frantal S, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Artner-Matuschek S, Kainberger F, Ritter M, Rinnerthaler G, Sevelda P, Bergh J, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Gampenrieder SP, Fohler H, Jakesz R, Fesl C, Singer C. Gnant M, et al. Among authors: jakesz r. NEJM Evid. 2022 Dec;1(12):EVIDoa2200162. doi: 10.1056/EVIDoa2200162. Epub 2022 Nov 18. NEJM Evid. 2022. PMID: 38319865 Clinical Trial.
Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
Singer CF; ABCSG; Holst F, Steurer S, Burandt EC, Lax SF, Jakesz R, Rudas M, Stöger H, Greil R; ABCSG; Sauter G, Filipits M; ABCSG; Simon R, Gnant M; ABCSG. Singer CF, et al. Among authors: jakesz r. Clin Cancer Res. 2022 Sep 15;28(18):4112-4120. doi: 10.1158/1078-0432.CCR-21-4328. Clin Cancer Res. 2022. PMID: 35920686 Free PMC article. Clinical Trial.
311 results